Coexistence of Anticoagulant and Anti-vascular Calcification Activities in 
*Kribbella* sp. UTMC 267 Metabolites

Fatemeh Salimi<sup>a,b</sup>, Javad Hamedi<sup>a,b,*</sup>, Elaheh Motevaseli<sup>*c</sup> and Fatemeh Mohammadipanah<sup>a,b</sup>

<sup>*Department of Microbial Biotechnology, School of Biology and Center of Excellence in Phylogeny of Living Organisms, College of Science, University of Tehran, Tehran, Iran. </sup>

<sup>aMicrobial Technology and Products Research Center, University of Tehran, Tehran, Iran. </sup>

<sup>cDepartment of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Science, Tehran, Iran. </sup>

**Abstract**

Thrombotic disorders increase the risk of cardiovascular/cerebrovascular complications and represent a major health problem worldwide. Anticoagulants are extensively used in treatment of these disorders. Vitamin K antagonists, like Warfarin, are frequently used in medication. Vascular calcification (VC) is a significant side-effect of vitamin K antagonists especially Warfarin. There is an urgent need to find natural, efficient, non-toxic, and cost effective anticoagulants without dangerous side-effect like VC. In the present study, we evaluated the potential of thirteen fermentation broth extracts of actinobacteria (FBEA) (200 µg mL<sup>-1</sup>) to prolong whole blood prothrombin time (PT)/international normalized ratio (INR) and activated partial thromboplastin time (APTT). The fractions of the most effective FBEA were further investigated for their inhibitory effect on VC. The results showed PT/INR of the healthy blood samples was sensitive to the presence of five FBEA. Their INR index fell in the 1.2 to 8.6 range and six FBEA prolonged both PT/INR and APTT parameters (1.7-5 INR, and 46-59 s for APTT). The fractions of *Kribbella* sp. UTMC 267 FBE (200 µg mL<sup>-1</sup>), as the most efficient FBE, only inhibited intrinsic and common pathways of coagulation (APTT). Under calcification condition, *Kribbella* sp. UTMC 267 fractions (20 µg mL<sup>-1</sup>) showed significant inhibitory effect on VC in alizarin red staining (13.3-76 %) and alkaline phosphatase activity of VSMCs (33-62%). They also inhibited osteopontin mRNA expression in treated vascular smooth muscle cells (VSMCs) under that situation. So, we can introduce *Kribbella* sp. UTMC 267 FBE as a good candidate for more investigation on thrombotic medication.

**Keywords:** Anticoagulant; Actinobacterial metabolites; Vascular calcification; Warfarin.

**Introduction**

According to the most recent world health organization (WHO) report, cardiovascular disease remains the leading cause of death worldwide. Thrombosis is identified as one of the leading disorders for cardiovascular disease like myocardial infarction and other complications including stroke and pulmonary embolism (1). Thus, anticoagulant and antiplatelet agents are effective therapy for prevention or reduction of thrombosis related mortality and morbidity in chronic hemodialysis patients (2).

There are several anticoagulant drugs with good efficacy; each of them inhibits the
coagulation through different mechanisms. These drugs include vitamin K antagonists such as Warfarin, and non-vitamin K antagonist oral anticoagulants (NOACs) like direct thrombin inhibitors and factor Xa inhibitors (3).

Warfarin is the most known vitamin K antagonist and has been an anticoagulant widely available for human use more than 60 years (4). Although Warfarin has showed an acceptable efficiency in medication, its multiple deleterious side-effects have also been well documented including drug-drug and food-drug interactions, slow dose-adjustment time, hemorrhage and recently recognized vascular calcification (VC) (5, 6). The patients with thrombotic complications who received Warfarin for long period of time suffer from extensive vascular calcification (VC) (7).

The effect of Warfarin on VC is explained by its inhibitory effect on the central and peripheral carboxylation cycle of several vitamin K-dependent calcification inhibiting factors, such as the matrix gla protein (MGP). Vitamin K is essential for the MGP activation (8). Functional vitamin K deficiency contributes to the high VC burden in haemodialysis patients (9). VC lead to increased prevalence of atherosclerosis, diabetic vasculopathy, chronic kidney disease, myocardial infarction, and hypertension (10-12).

Non-vitamin K antagonist oral anticoagulants (NOACs) are suitable alternatives for vitamin K antagonists, although recent investigation indicated some of their side-effects including increased risk of life-threatening bleeding (13). In addition, NOACs are substrate of cytochrome P450 (CYP) isoenzyme 3A4 and P-glycoprotein (P-gp) transporter. Therefore, co-administration of NOACs with P-gp or CYP3A4 inducers or inhibitors may impact exposure to the NOAC (14-17). Moreover, many rate-controlling and anti-arrhythmic drugs can interfere with action of NOACs (16).

All of these reasons prompt for the investigation of natural products with considerable anticoagulant activity and inhibitory effect on VC as attractive alternatives to attenuate VC progression for patients who have consumed Warfarin for a long period of time and now have high burden of VC in comparison to healthy peoples.

For finding biocompounds with anticoagulant and anti-VC activities, natural sources of potent compounds can be selected for screening program. Among these bio-libraries, actinobacteria are of the best candidates. These bacteria provide useful antibacterial, antifungal (18), antiviral (19), immunosuppressive (20), anticancer (21), anti-diabetes (22), anti-obesity (22) and other pharmacologically effective metabolites. According to our best of knowledge, there is no report on the actinobacterial metabolites with both anti-coagulant and anti-VC activities. Therefore, discovering new anticoagulant compounds with anti-VC activity is becoming increasingly important as more and more because thrombotic complications and VC are directly related to cardiovascular mortality and morbidity worldwide. The goals of the present study were the screening of FBEA for anticoagulant activity, selection of most efficient FBE and its fractionation, purification and finally introduction of an actinobacterium with inhibitory effect on VC.

**Experimental**

**Actinbacterial strains**

Thirteen actinobacterial strains including *Streptomyces* and rare actinomycetes were isolated from different geographical locations in Iran and were deposited in University of Tehran Microorganisms Collection (UTMC) and were used throughout the study.

**Seeding and fermentation processes**

The seed culture (namely FA medium which consists (g L⁻¹): starch 10, yeast extract 4, and peptone 2) of each strains was prepared and kept on shaking incubator at 180 rpm and 28 °C for 2 days. Then, 5% (v/v) of the inoculum was transferred to the fermentation medium (FA medium), at 28 °C for 7 days in shaking incubator at 180 rpm.

**The biocompounds extraction process**

After seven days, the fermentation broth was centrifuged at 2300 g for 15 min and the fermentation broth extracts of actinobacteria (FBEA) were obtained from the supernatant using equal volume of ethyl acetate. The
solvent phase was evaporated in rotary vacuum evaporator. The obtained FBEA were preserved at -20 °C until use. The extract of un-inoculated FA medium (culture medium extract) was obtained to make sure that putative bioactivities of FBEA are not due to the presence of these compounds in the intact medium.

**Anticoagulant activities of FBEA**

The effect of FBEA on coagulation parameters including prothrombin time (PT) and activated partial thromboplastin time (APTT) were evaluated. In brief, 100 μL of FBEA (200 μg mL⁻¹) were mixed with 100 μL of human plasma and warmed at 37 °C for 180 s. Then, 200 μL of thromboplastin reagent was loaded and PT was measured. For APTT measurement, the mixture of 100 μL FBEA and 100 μL of human plasma were warmed at 37 °C for 60 s, then 100 μL of APTT reagent was added. It was activated for 300 s and APTT was measured after the addition of 100 μL of 25 mM CaCl₂ (23). The inhibitory effects of the most efficient FBEA’s fractions on vascular calcification

To explore the inhibitory effect of the most efficient FBEA’s fractions on vascular calcification, VSMCs (A7r5 cell line, 1×10⁴ cells/plate) were incubated in 24-well plates containing Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10 mM of sodium pyruvate and 5% FBS in the presence of beta-glycerophosphate (BGP) (10 mM) and CaCl₂ (3 mM) (calcifying medium) to permit maximal mineralization for 14 days. Then, the amount of calcification in A7r5 cells was measured by alizarin red staining and quantitative data were obtained using cetylpyridinium chloride which dissolves attached stain to calcification nodules (24).

Inhibition% = (Absorbance of the calcification group - Absorbance of the treatment group / Absorbance of the calcification group) × 100

**Measurement of ALP activity in presence of the most efficient FBEA’s fractions**

The inhibitory activity of the most efficient FBEA’s fractions on ALP activity of VSMCs was investigated under calcification conditions. The extract of un-inoculated FA medium and Levamisole were used as the blank and the positive control, respectively (25). A7r5 cells (4 × 10⁵ cells/well) were incubated in the calcification condition for 14 days, then the cells were washed with phosphate buffered saline (PBS), and the proteins in the cells were extracted using the lysis buffer (10 mM Tris–HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mL Triton X-100, 5 mM glycerol and 0.01 g SDS in 100 mL ddH₂O). The alkaline phosphatase (ALP) activity was determined using p-nitrophenyl phosphate as a substrate. The enzymatic activity was normalized to the total protein concentration. The protein was measured using the standard Bradford method (25).

**The inhibitory effects of the most efficient FBEA’s fractions on osteogenic gene expression**

The effect of the most efficient FBEA’s fractions on the expression of bone-related
gene markers in VSMCs under the calcification conditions was determined through real time PCR. Total RNA was isolated from the VSMCs using Trizol (Invitrogen) and reverse-transcribed into cDNA using a cDNA synthesis kit (Takara). The applied primers were as follow: rat osteopontin (OPN) F-5’ CCACAGTCGATGTCCCTGAC3’, R-5’ TGTGGCATCGGGATACTGTT3’, and Runx2 F-5’ GGCCACTTACCACAGAGCTA3’, R-5’ AGGCCGTCAGAGAACAAACT3’.

The relative quantities of the transcripts were determined using a standard curve and were normalized against HPRT (Hypoxanthine-guanine phosphoribosyltransferase). The transcripts were amplified in following cycles: 95 ℃, 15 s; 95 ℃, 15 s; 60 ℃ 15 s, for 40 cycles. Rotor-Gene 6000 Series software version 1.7 and REST software were used for the analysis of the results.

Measurement the anti-coagulation activity of the most efficient FBE’s fractions

Anticoagulation activity of the most efficient FBE’s fractions (200 μg mL−1) was evaluated using APTT and PT tests as described, previously.

Investigating cytotoxicity of the most efficient FBEA’s fractions using MTT assay

The cytotoxicity profile of the most efficient FBEA’s fractions on VSMCs (A7r5 cell line) was determined using MTT test (26). The stock solution of the fractions was prepared in DMSO and was diluted by DMEM medium to prepare 20, 50, 100, 150, 200 μg mL−1 concentrations of FBEA. The absorbance of the untreated cells (the control group) was considered as 100% viability. The viability of the cells exposed to the most efficient FBEA’s fractions was calculated as follows:

Viability% = (the Absorbance of the Treatment Group / the Absorbance of the Control Group) × 100

Results

The Anticoagulant activity of FBEA

Among tested FBEA, rather than Promicromonospora iranensis UTMC 792, twelve FBEA showed anticoagulant activity (Table 1). FBE of Streptomyces sp. UTMC 2189 enhanced APTT and had no effect on PT. Both coagulation parameters (APTT and PT) were significantly prolonged in the plasma containing FBE of Kribbella sp. UTMC 267 in comparison with that of the normal control plasma. It means that this FBE has the best inhibitory effect on extrinsic, intrinsic and/or final common pathways of coagulation, and therefore was selected for further investigations.

Anti-vascular calcification activity of the Kribbella sp. UTMC 267 FBE’s fractions

From eighty liters of Kribbella sp. UTMC 267 fermentation broth, 20 grams FBE were taken. After loading it in Silica gel containing column and eluting the column with dichloromethane: methanol, several fractions with various polarities were obtained. After observing TLC profile of the fractions, the fractions with the same pattern were mixed together. Finally, two fractions with 0-20% and 30-100% polarities were obtained and designated as I and II fractions, respectively (Figure 1). These fractions (20 μg mL−1) showed 72% and 26% anti-VC activity, respectively. Therefore, the fraction I with higher anti-VC activity was further fractioned using Sephadex column chromatography. The obtained fractions (I-A, I-B, I-C and I-D) (20 μg mL−1) showed significant anti-VC in the range of 13.3-76 % (Figure 2). The fraction I-D showed the most anti-VC activity. The calcified nodules were developed throughout the cell culture in the calcification group without FBEA (BGP + CaCl₂). The number and the size of the calcification nodules were considerably reduced in the treatment groups (Figure 3). The extract of un-inoculated FA medium also cannot inhibit vascular calcification and the calcification nodules can be observed (Figure 3).

The inhibitory effect of the Kribbella sp. UTMC 267 fractions on ALP activity

ALP activity in the treatment groups was lower than that of in the VSMCs of the calcification group without fractions (p < 0.05). The Levamisole (positive control) and the extract of the intact FA medium (blank) also showed 17.25% and 6.2 5% inhibitory effect on ALP activity, respectively (Figure 4).
Table 1. Anticoagulation activity of the fermentation broth extract of actinobacteria (200 µg mL\(^{-1}\)) using prothrombin time (PT), and activated partial thromboplastin time (APTT) assays. The results expressed in seconds. PT results also expressed as international normalized ratio (INR). PBS was used as blank. * indicated the significant anticoagulant activity.

| UTMC code of the strains | Strain Name            | PT\(^1\) (sec) | INR\(^2\)  | APTT\(^1\) (sec) |
|--------------------------|------------------------|----------------|------------|------------------|
| Blank                    | -                      | 13             | 1          | 37               |
| 792                      | Promicromonospora iranensis | 13             | 1          | 37               |
| 103                      | Nocardiopsis arvandia   | 14.1*          | 1.2        | 30               |
| 102                      | Nocardiopsis sinuspersici | 15.1*         | 1.3        | 35               |
| 533                      | Promicromonospora sp.   | 14.1*          | 1.2        | 32               |
| 1143                     | Actinophytocola timorensis | 14.1*        | 1.2        | 37               |
| 2171                     | Nocardiosis sp.         | 38.2*          | 8.6        | 37               |
| 2189                     | Streptomyces sp         | 13             | 1          | 40*              |
| 522                      | Kribbella sp.           | 14.1*          | 1.2        | 39*              |
| 693                      | Kribbella shirazensis   | 17*            | 1.7        | 58*              |
| 751                      | Nocardia sp             | 17*            | 1.7        | 46*              |
| 557                      | Nocardia soli           | 16*            | 1.5        | 59*              |
| 2243                     | Promicromonospora sp.   | 29.1*          | 5          | 40*              |
| 267                      | Kribbella sp.           | 28*            | 4.7        | 48*              |

*Normal PT and APTT value were recorded as 12-14 s and 24-37 s, respectively (23). INR is the ratio of the treatment’s prothrombin time and the normal mean prothrombin time (1).

![Figure 1](image_url)

**Figure 1.** TLC pattern of the fermentation broth extract of *Kribbella* sp. UTMC 267 under UV light (256 and 366 nm) and anisaldehyde staining. The fractions with the same TLC pattern were mixed together, finally four fractions were obtained and designated I-A, I-B, I-C and I-D.
The inhibitory effect of Kribbella sp. UTMC 267 FBE’s fractions on osteoblastic gene expression in VSMCs under the calcification conditions

In comparison to the calcification group, the expression of OPN was significantly decreased in the fraction I-A and I-B treatment groups by 6.9 and 4 fold, respectively ($P < 0.05$), while, these fractions could not prevent Runx2 mRNA upregulation ($P > 0.05$). The fraction I-C and I-D have no effect on OPN and Runx2 mRNA expression ($P > 0.05$).

Anti-coagulation activity of Kribbella sp. UTMC 267 fractions

The results showed that Kribbella sp.
Anticoagulant and Anti-vascular Calcifier Actinobacterium

UTMC 267 fractions can just have effect on intrinsic and/or final common pathways of coagulation cascade because they only enhanced APTT. I-A, I-B, I-C, and I-D fractions delay coagulation in APTT test for seconds (50, 52, 40, and 40 s, respectively) and has no effect on extrinsic pathway which was evaluated by PT test (13 s), suggesting a preferential action toward the intrinsic and/or common pathway of coagulation.

The evaluation of Kribbella sp. UTMC 267 FBE's fractions toxicity

Kribbella sp. UTMC 267 FBE fractions at the concentrations of 20-200 µg mL$^{-1}$ showed limited toxicity. The treated cells showed more than 80% viability in all applied concentrations. The fraction D showed proliferative activity on A7r5 cell line in all investigated concentrations (Table 2).

Discussion

Several reports have shown high load of VC in the patients with current or past Warfarin use. This association is consistent with inhibition of MGP. Warfarin blocks MGP carboxylation and its subsequent activation, consequently aggravates VC (9, 27). Therefore, finding natural and cost-effective compounds with both anti-coagulant and anti-VC activities is so critical for the hemodialysis patients who are faced with life-threatening complications related to the coagulation disorders and VC (28).

The results of this study showed that FBEA have significant potency to inhibit blood

| FBE’s fractions | 20 (µg mL$^{-1}$) | 50 (µg mL$^{-1}$) | 100 (µg mL$^{-1}$) | 150 (µg mL$^{-1}$) | 200 (µg mL$^{-1}$) |
|-----------------|----------------|----------------|----------------|----------------|----------------|
| Viability rate (%) of treated A7r5 cells |
| I               | 107.03         | 99.48          | 107.55         | 104.16         | 105.53         |
| II              | 95.4           | 90.17          | 106.83         | 103.19         | 93.36          |
| I-A             | 104.17         | 90.36          | 93.36          | 97.39          | 84.37          |
| I-B             | 99.87          | 93.81          | 99.67          | 83.92          | 91.79          |
| I-C             | 108.33         | 93.88          | 85.42          | 83.92          | 89.52          |
| I-D             | 106.51         | 118.42         | 122.20         | 116.21         | 125.72         |

Figure 4. The inhibitory effect of the fermentation broth extract fractions of Kribbella sp. UTMC 267 (20 µg mL$^{-1}$) on alkaline phosphatase (ALP) activity of vascular smooth muscle cell. All cells were incubated in the presence of β-glycerophosphate and CaCl$_2$. Levamisole (20 µg mL$^{-1}$) was used as alkaline phosphatase inhibitor control. The bars indicated the mean ± standard error (n = 3). The inhibitory effect of un-inoculated culture medium extract (20 µg mL$^{-1}$) on ALP activity was also evaluated.
coagulation due to their ability to prolong coagulation processes in the samples of human blood which were determined by PT (contact activation pathway) and APTT (tissue factor pathway) in the clinical diagnostic lab-based assays (29, 30). However, their inhibitory mechanisms are not fully understood; because there are some coagulation factors in both pathways. The factors, including II, V, VIII, IX, and XI comprise the intrinsic clotting cascade, and any anticoagulant that affects the activity of these factors can influence the APTT and the factors, including I, II, III, VII, V and X have also critical role in extrinsic pathway of coagulation, so compounds with inhibitory effect on them can prolong PT (13).

It is likely that Kribbella sp. UTMC 267 FBE, the most efficient FBE (INR 4.7 and in APTT 48 s), may have inhibitory effect on one or more coagulant factors in extrinsic, intrinsic and/or common pathway of blood coagulation.

Our experiments proved the presence of biocompounds with anticoagulant activity in the FBEA which can be extracted by ethyl acetate. It means our extraction method is suitable for these biocompounds extraction. These results may be explained by the presence of anticoagulant, anti-thrombotic and fibrinolytic agents in the bacterial extracts especially in the actinobacterial fermentation broth (31, 32). Some recent studies showed that actinobacteria produce compounds with anti-coagulation activities. Coumarin 6-ol, 3,4-dihydro-4,4,5,7-tetramethyl- (CDTM) and 2-(4-Amino-imidazol-[4,5-d]piridazin-1-il)-5-hidroximetil-4-metil-tetrahidrofuran-3-ol are compounds with anticoagulant and anti-thrombotic activities which have been discovered from marine Streptomyces sp. and Salinispora arenicola, respectively (33, 34).

It has been predicted that no vitamin K antagonist exists in Kribbella sp. UTMC 267 FBE fractions because it has been shown that Kribbella sp. UTMC 267 FBE’s fractions have inhibitory effect on VC. It seems that they have no inhibitory effect on MGP, which involved in inhibition of vascular calcification. Kribbella sp. UTMC 267 fractions (especially I-A, I-B and I-D fractions) obviously decrease the size and number of calcification nodules and other osteogenic marker such as alkaline phosphatase activity of A7r5 cells and OPN mRNA expression in the calcification condition.

In addition, it has been shown that Kribbella sp. UTMC 267 fractions are not toxic in the concentrations up to 200 µg mL⁻¹ on A7r5 cells. The cells in all treatment groups showed more than 80% viability. The incubated cells showed no significant morphological change in all investigated concentrations of Kribbella sp. UTMC 267 fractions. The nontoxic property of these fractions can reinforce their therapeutic potential as future anti-thrombosis and anti-VC drug candidates, with particular emphasis on their therapeutic potential in the treatment of cardiovascular and cerebrovascular diseases.

One of the most notable achievements of this study is introducing the metabolites of Kribbella sp. UTMC 267 as promising candidates for co-administration with Warfarin to potentiate its anticoagulation activity and decrease its life-threatening side-effect, vascular calcification. Their synergic effect can help in better management of thrombotic disorders with the least side-effects. In conclusion, this study for the first time attempted to indicate the simultaneously presence of pharmacologically active anticoagulant and anti-VC agents in the tested actinobacterial metabolites that could be isolated and evaluated for clinical and physiological applications as natural alternatives.

Declaration of conflicting interests
The authors declare that they have no conflicts of interest.

Ethical consideration
This study has been performed in accordance with ethical standards and in compliance with bioethical rules for working with cell lines and microbial strains. No experiments have yet been conducted on humans or animals for this study.

References
(1) Nansseu JRN and Noubiap JJN. Aspirin for primary prevention of cardiovascular disease. Thromb. J. (2015) 13: 1.
(2) Chan KE, Lazarus JM, Thadhani R and Hakim RM. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am. Soc. Nephrol. (2009) 20: 872-81.
Anticoagulant and Anti-vascular Calcifier Actinobacterium

(3) Husled S, de Caterina R, Andreotti F, Arnesen H, Bachmann F, Huber K, Jespersen J, Kristensen SD, Lip G and Morais J. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. *Thromb. Haemost.* (2014) 111: 781-2.

(4) Mega JL and Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. *Lancet* (2015) 386: 281-91.

(5) January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Conti JB, Ellison PT, Ezekowitz MD, Field ME and Murray KT. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J. Am. Coll. Cardiol.* (2014) 64: e1-e76.

(6) Whittaker P, Donovan J and Przyklenk K. Long-term warfarin therapy is associated with tissue calcification. *J. Thromb. Thrombolysis* (2008) 25: 125.

(7) Chatrou ML, Winckers K, Hackeng TM, Reutelingsperger CP and Schurgers LJ. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. *Blood Rev.* (2012) 26: 155-66.

(8) Danzer J. Vitamin K-dependent proteins, warfarin, and vascular calcification. *J. Am. Soc. Nephrol.* (2008) 3: 1504-10.

(9) Caluwé R, Pyfheroen L, De Boeck K and De Vriese AS. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. *Clin. Kidney J.* (2016) 9:273-9.

(10) Johnson RC, Leopold JA and Loscalzo J. Vascular calcification pathobiological mechanisms and clinical implications. *Circ. Res.* (2006) 99: 1044-59.

(11) Shao J-S, Cai J and Towler DA. Molecular mechanisms of vascular calcification lessons learned from the aorta. *Arterioscler. Thromb. Vasc. Biol.* (2006) 26: 1423-30.

(12) Trion A and van der Laarse A. Vascular smooth muscle cells and calcification in atherosclerosis. *Am. Heart J.* (2004) 147: 808-14.

(13) Jackson II LR and Becker RC. Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. *J. Thromb. Thrombolysis* (2014) 37: 380-91.

(14) Härtter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W and Reilly PA. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. *Br. J. Clin. Pharmacol.* (2012) 74: 490-500.

(15) Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G and Shi M. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. *Am. J. Cardiovasc. Drugs* (2013) 13: 331-42.

(16) Mueck W, Kubitz D and Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. *Br. J. Clin. Pharmacol.* (2013) 76: 455-66.

(17) Mikkaichi T, Yoshigai Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, Okudaira N and Izumi T. Edoxaban transport via P-glycoprotein is a key factor for the drug’s disposition. *Drug Metab. Dispos.* (2014) 42: 520-8.

(18) Fang LZ, Kun XC, Song ZC, Qin XJ, Qin HY, Qun DC and He MM. Fungistatic intensity of agricultural soil against fungal agents and phylogenetic analysis on the actinobacteria involved. *Curr. Microbiol.* (2011) 62: 1152-9.

(19) Han L, Zhang G, Miao G, Zhang X and Feng J. *Streptomyces kanasensis* sp. nov., an antiviral glycoprotein producing actinomycete isolated from forest soil around kanas lake of China. *Curr. Microbiol.* (2015) 71: 627-31.

(20) Arndt C, Cruz MC, Cardenas ME and Heitman J. Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing *Saccharomyces cerevisiae* and *Cryptococcus neoformans*. *Microbiology* (1999) 145: 1989-2000.

(21) Naine J, Srivivasan M and Devi S. Novel anticancer compounds from marine actinomycetes: a review. *J. Pharm. Res.* (2011) 4: 1285-7.

(22) Schwientek P, Szczepanowski R, Rückert C, Kalinowski J, Klein A, Selker B, Wehmeier UF, Stoye J and Pühler A. The complete genome sequence of the acarbose producer *Actinoplanes* sp. *SE50/110*. *BMC Genomics* (2012) 13: 112.

(23) Li J, Tong T, Ko D-O and Kang S-G. Anti-thrombotic potential of extracts from abalone, *Haliotis Discus* (Common abalone) and the price to pay for anticoagulation therapy with vitamin K-antagonists. *Blood Rev.* (2012) 26: 155-66.

(24) Shioi A, Nishizawa Y, Jono S, Koyama H, Hosoi M and Morii H. β-Glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. *Arterioscler. Thromb. Vasc. Biol.* (1995) 15: 2003-9.

(25) Sila-asna M and Bunyaratvej A. Kobe University Repository: Kernel. *Kobe. J. Med. Sci.* (2007) 53: 25-35.

(26) Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods* (1983) 65: 55-63.

(27) Tantisattamo E, Han KH and O’Neill WC. Increased vascular calcification in patients receiving warfarin. *Arterioscler. Thromb. Vasc. Biol.* (2015) 35: 237-42.

(28) Hughes M and Lip G. Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. *Thromb. Haemost.* (2008) 99: 295-304.

(29) Rice TW and Wheeler AP. Coagulopathy in critically ill patients: part 1: platelet disorders. *Chest J.* (2009) 136: 1622-30.

(30) Dahlbäck B. Blood coagulation. *Lancet* (2000) 355: 467.
1627-32.

(31) Tamura Y, Okada K, Kawao N, Yano M, Ueshima S, Nagai N and Matsuo O. Profibrinolytic effect of Enzamin, an extract of metabolic products from Bacillus subtilis AK and Lactobacillus. *J. Thromb. Thrombolysis* (2011) 32: 195-200.

(32) Babu V and Devi CS. *In-vitro* thrombolytic activity of purified streptokinase extracted from *Streptococcus equinus* VIT_VB2 isolated from bovine milk. *J. Thromb. Thrombolysis* (2015) 39: 71-8.

(33) Íñiguez-Martínez AM, Cardoso-Martínez F, de la Rosa J, Cueto M, Díaz-Marrero A, Darias J, Becerril-Espinosa A, Plata-Rosas LJ and Soria-Mercado IE. Compuestos aislados de Salinispora arenicola del Golfo de California, México. *Rev. Biol. Mar. Oceanogr*. (2016) 51: 161-70.

(34) Abirami M, Gopal J and Kannabiran K. Extraction and identification of antibacterial compound from marine Streptomyces sp. VITAK1 isolated from the coast of Andaman and Nicobar Islands, India. *Appl. Biochem. Microbiol*. (2015) 51: 406-10.

This article is available online at http://www.ijpr.ir